Bladder preservation in the treatment of muscle-invasive bladder cancer (MIBC): A review of the literature and a practical approach to therapy

BJU International

Volumn 112, Issue 1, 2013, Pages 13-25

  Smith, Zachary L ^a   Christodouleas, John P ^a   Keefe, Stephen M ^a   Malkowicz, S Bruce ^a   Guzzo, Thomas J ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

bladder cancer; bladder preservation; bladder sparing; chemotherapy; muscle invasive; radiation therapy

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; FLUOROURACIL; GEMCITABINE; METHOTREXATE; MITOMYCIN; PACLITAXEL; TRASTUZUMAB; VINBLASTINE;

ADVERSE OUTCOME; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CYSTECTOMY; DOSE RESPONSE; EXTERNAL BEAM RADIOTHERAPY; HUMAN; LYMPH NODE DISSECTION; MULTIMODAL CHEMOTHERAPY; MULTIPLE CYCLE TREATMENT; MUSCLE INVASIVE BLADDER CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; REVIEW; SALVAGE THERAPY; SURVIVAL RATE; SURVIVAL TIME; TRANSURETHRAL RESECTION;

CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; CYSTECTOMY; HUMANS; MUSCLE NEOPLASMS; MUSCLE, SMOOTH; NEOPLASM INVASIVENESS; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 84879101827     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11762.x     Document Type: Review

References (85)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29
2. Ro JY, Staerkel GA, Ayala AG,. Cytologic and histologic features of superficial bladder cancer. Urol Clin North Am 1992; 19: 435-453
3. Saad A, Hanbury DC, McNicholas TA, Boustead GB, Morgan S, Woodman AC,. A study comparing various noninvasive methods of detecting bladder cancer in urine. BJU Int 2002; 89: 369-373
4. Soloway MS, Sofer M, Vaidya A,. Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol 2002; 167: 1573-1583
5. Skinner DG, Stein JP, Lieskovsky G, et al. 25-year experience in the management of invasive bladder cancer by radical cystectomy. Eur Urol 1998; 33 (Suppl. 4): 25-26
6. Hadjizacharia P, Stein JP, Cai J, Miranda G,. The impact of positive soft tissue surgical margins following radical cystectomy for high-grade, invasive bladder cancer. World J Urol 2009; 27: 33-38
7. Herr HW, Faulkner JR, Grossman HB, et al. Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol 2004; 22: 2781-2789
8. Stein JP,. The role of lymphadenectomy in patients undergoing radical cystectomy for bladder cancer. Curr Oncol Rep 2007; 9: 213-221
9. Aghazadeh MA, Barocas DA, Salem S, et al. Determining factors for hospital discharge status after radical cystectomy in a large contemporary cohort. J Urol 2011; 185: 85-89
10. Rosario DJ, Becker M, Anderson JB,. The changing pattern of mortality and morbidity from radical cystectomy. BJU Int 2000; 85: 427-430
11. Goodney PP, Stukel TA, Lucas FL, Finlayson EV, Birkmeyer JD,. Hospital volume, length of stay, and readmission rates in high-risk surgery. Ann Surg 2003; 238: 161-167
12. Shabsigh A, Korets R, Vora KC, et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol 2009; 55: 164-174
13. Maderbacher S, Schmidt J, Eberle JM, et al. Long-term outcome of ileal conduit diversion. J Urol 2003; 169: 985-990
14. Pagano F, Bassi P, Galetti TP, et al. Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification. J Urol 1991; 145: 45-50
15. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol 2001; 19: 666-675
16. Thrasher JB, Frazier HA, Robertson JE, Paulson DF,. Does of stage pT0 cystectomy specimen confer a survival advantage in patients with minimally invasive bladder cancer? J Urol 1994; 152: 393-396
17. Volkmer BG, Kuefer R, Bartsch G Jr, et al. Effect of a pT0 cystectomy specimen without neoadjuvant therapy on survival. Cancer 2005; 104: 2384-2391
18. Hall RR,. Transurethral resection of transitional cell carcinoma. Prob Urol 1992; 6: 460-471
19. Mydlo JH, Weinstein R, Shah S, Solliday M, Macchia RJ,. Long-term consequences from bladder perforation and/or violation in the presence of transitional cell carcinoma: results of a small series and a review of the literature. J Urol 1999; 161: 1128-1132
20. Flocks RH,. Treatment of patients with carcinoma of the bladder. J Am Med Assoc 1951; 145: 295-301
21. Milner WA,. The role of conservative surgery in the treatment of bladder tumours. Br J Urol 1954; 26: 375-386
22. O'Flynn JD, Smith JM, Hanson JS,. Transurethral resection for the assessment and treatment of vesical neoplasms: a review of 840 consecutive cases. Eur Urol 1975; 1: 38-40
23. Barnes RW, Dick AL, Hadley HL, Johnston OL,. Survival following transurethral resection of bladder carcinoma. Cancer Res 1977; 37: 2895-2897
24. Henry K, Miller J, Mori M, Loening S, Fallon B,. Comparison of transurethral resection to radical therapies for stage B bladder tumors. J Urol 1988; 140: 964-967
25. Malkowicz SB, Nichols P, Lieskovsky G, Boyd SD, Huffman J, Skinner DG,. The role of radical cystectomy in the management of high grade superficial bladder cancer (PA, P1, PIS and P2). J Urol 1990; 144: 641-645
26. Karakiewicz PI, Shariat SF, Palapattu GS, et al. Precystectomy nomogram for prediction of advanced bladder cancer stage. Eur Urol 2006; 50: 1254-1262
27. Kibel AS, Dehdashti F, Katz MD, et al. Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol 2009; 27: 4314-4320
28. Solsona E, Iborra I, Ricos JV, Monros JL, Casanova J, Calabuig C,. Feasibility of transurethral resection for muscle infiltrating carcinoma of the bladder: long-term followup of a prospective study. J Urol 1998; 159: 95-99
29. Leibovici D, Kassouf W, Pisters LL, et al. Organ preservation for muscle-invasive bladder cancer by transurethral resection. Urology 2007; 70: 473-476
30. Herr HW,. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol 2001; 19: 89-93
31. Solsona E, Iborra I, Collado A, Rubio-Briones J, Casanova J, Calatrava A,. Feasibility of radical transurethral resection as monotherapy for selected patients with muscle invasive bladder cancer. J Urol 2010; 184: 475-480
32. Kassouf W, Swanson D, Kamat AM, et al. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience. J Urol 2006; 175: 2058-2062
33. Pontes JE, Lopez R,. Tumor recurrence following partial cystectomy. Prog Clin Biol Res 1984; 162A: 387-392
34. Lindahl F, Jorgensen D, Egvad K,. Partial cystectomy for transitional cell carcinoma of the bladder. Scand J Urol Nephrol 1984; 18: 125-129
35. Novick AC, Stewart BH,. Partial cystectomy in the treatment of primary and secondary carcinoma of the bladder. J Urol 1976; 116: 570-574
36. Resnick MI, O'Conor VJ Jr,. Segmental resection for carcinoma of the bladder: review of 102 patients. J Urol 1973; 109: 1007-1010
37. Long RT, Grummon RA, Spratt JS Jr, Perez-Mesa C,. Carcinoma of the urinary bladder. Comparison with radical, simple, and partial cystectomy and intravesical formalin. Cancer 1972; 29: 98-105
38. Peress JA, Waterhouse K, Cole AT,. Complications of partial cystectomy in patients with high grade bladder carcinoma. J Urol 1977; 118: 761
39. Faysal MH, Freiha FS,. Evaluation of partial cystectomy for carcinoma of bladder. Urology 1979; 14: 352-356
40. Evans RA, Texter JH Jr,. Partial cystectomy in the treatment of bladder cancer. J Urol 1975; 114: 391-393
41. Kaneti J,. Partial cystectomy in the management of bladder carcinoma. Eur Urol 1986; 12: 249-252
42. Holzbeierlein JM, Lopez-Corona E, Bochner BH, et al. Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection. J Urol 2004; 172: 878-881
43. Smaldone MC, Jacobs BL, Smaldone AM, Hrebinko RL Jr,. Long-term results of selective partial cystectomy for invasive urothelial bladder carcinoma. Urology 2008; 72: 613-616
44. Koga F, Kihara K, Yoshida S, et al. Selective bladder-sparing protocol consisting of induction low-dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle-invasive bladder cancer: oncological outcomes of the initial 46 patients. BJU Int 2012; 109: 860-866
45. Fossa SD, Aass N, Ous S, Waehre H, Ilner K, Hannisdal E,. Survival after curative treatment of muscle-invasive bladder cancer. Acta Oncol 1996; 35 (Suppl. 8): 59-65
46. Rosenberg JE, Carroll PR, Small EJ,. Update on chemotherapy for advanced bladder cancer. J Urol 2005; 174: 14-20
47. Duncan W, Quilty PM,. The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage X-ray therapy. Radiother Oncol 1986; 7: 299-310
48. Gospodarowicz MK, Quilty PM, Scalliet P, et al. The place of radiation therapy as definitive treatment of bladder cancer. Int J Urol 1995; 2 (Suppl. 2): 41-48
49. Majewski W, Maciejewski B, Majewski S, Suwinski R, Miszczyk L, Tarnawski R,. Clinical radiobiology of stage T2-T3 bladder cancer. Int J Radiat Oncol Biol Phys 2004; 60: 60-70
50. Pollack A, Zagars GK, Swanson DA,. Muscle-invasive bladder cancer treated with external beam radiotherapy: prognostic factors. Int J Radiat Oncol Biol Phys 1994; 30: 267-277
51. Choueiri TK, Raghavan D,. Chemotherapy for muscle-invasive bladder cancer treated with definitive radiotherapy: persisting uncertainties. Nat Clin Pract Oncol 2008; 5: 444-454
52. Rodel C, Grabenbauer GG, Kuhn R, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 2002; 20: 3061-3071
53. Housset M, Maulard C, Chretien Y, et al. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol 1993; 11: 2150-2157
54. Rodel C, Weiss C, Sauer R,. Trimodality treatment and selective organ preservation for bladder cancer. J Clin Oncol 2006; 24: 5536-5544
55. Shipley WU,. Full-dose irradiation for invasive bladder cancer: prognostic factors and techniques. Urology 1984; 23: 95-100
56. Thariat J, Caullery M, Ginot A, et al. [State of the art and advances in radiotherapy for bladder cancer]. Prog Urol 2009; 19: 85-93
57. Jenkins BJ, Caulfield MJ, Fowler CG, et al. Reappraisal of the role of radical radiotherapy and salvage cystectomy in the treatment of invasive (T2/T3) bladder cancer. Br J Urol 1988; 62: 343-346
58. Pollack A, Zagars GZ,. Radiotherapy for stage T3b transitional cell carcinoma of the bladder. Semin Urol Oncol 1996; 14: 86-95
59. Mameghan H, Fisher R, Mameghan J, Brook S,. Analysis of failure following definitive radiotherapy for invasive transitional cell carcinoma of the bladder. Int J Radiat Oncol Biol Phys 1995; 31: 247-254
60. Efstathiou JA, Bae K, Shipley WU, et al. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol 2009; 27: 4055-4061
61. Miyanaga N, Akaza H, Okumura T, et al. A bladder preservation regimen using intra-arterial chemotherapy and radiotherapy for invasive bladder cancer: a prospective study. Int J Urol 2000; 7: 41-48
62. Viswanathan AN, Yorke ED, Marks LB, Eifel PJ, Shipley WU,. Radiation dose-volume effects of the urinary bladder. Int J Radiat Oncol Biol Phys 2010; 76: S116-122
63. Horwich A, Dearnaley D, Huddart R, et al. A randomised trial of accelerated radiotherapy for localised invasive bladder cancer. Radiother Oncol 2005; 75: 34-43
64. Pos FJ, Hart G, Schneider C, Sminia P,. Radical radiotherapy for invasive bladder cancer: what dose and fractionation schedule to choose? Int J Radiat Oncol Biol Phys 2006; 64: 1168-1173
65. Zietman AL, Sacco D, Skowronski U, et al. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. J Urol 2003; 170: 1772-1776
66. Nieuwenhuijzen JA, Pos F, Moonen LM, Hart AA, Horenblas S,. Survival after bladder-preservation with brachytherapy versus radical cystectomy; a single institution experience. Eur Urol 2005; 48: 239-245
67. Pos F, Horenblas S, Dom P, Moonen L, Bartelink H,. Organ preservation in invasive bladder cancer: brachytherapy, an alternative to cystectomy and combined modality treatment? Int J Radiat Oncol Biol Phys 2005; 61: 678-686
68. James ND, Hussain SA, Hall E, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 2012; 366: 1477-1488
69. Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK,. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 2011; 29: 2171-2177
70. Herr HW, Dotan Z, Donat SM, Bajorin DF,. Defining optimal therapy for muscle invasive bladder cancer. J Urol 2007; 177: 437-443
71. Galsky MD, Hahn NM, Rosenberg J, et al. Treatment of patients with metastatic urothelial cancer 'unfit' for cisplatin-based chemotherapy. J Clin Oncol 2011; 29: 2432-2438
72. Hussain MH, Glass TR, Forman J, et al. Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study. J Urol 2001; 165: 56-60
73. Sweeney P, Kursh ED, Resnick MI,. Partial Cystectomy. Urol Clin North Am 1992; 19: 701-711
74. Shipley WU, Kaufman DS, Tester WJ, Pilepich MV, Sandler HM,. Overview of bladder cancer trials in the Radiation Therapy Oncology Group. Cancer 2003; 97: 2115-2119
75. Zietman AL, Hunt D, Kaufman DS, et al. Preliminary Results of RTOG 0233: a Phase II Randomized Trial for Muscle-invading Bladder Cancer Treated by Transurethral Resection and Radiotherapy Comparing Two Forms of Concurrent Induction Chemotherapy. Int J Radiat Oncol Biol Phys 2010; 78 (3 Suppl): S31-S32
76. Efstathiou JA, Spiegel DY, Shipley WU, et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol 2012; 61: 705-711
77. Krause FS, Walter B, Ott OJ, et al. 15-year survival rates after transurethral resection and radiochemotherapy or radiation in bladder cancer treatment. Anticancer Res 2011; 31: 985-990
78. Hautmann RE, Gschwend JE, de, Petriconi RC, Kron M, Volkmer BG,. Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol 2006; 176: 486-492
79. Madersbacher S, Hochreiter W, Burkhard F, et al. Radical cystectomy for bladder cancer today-a homogeneous series without neoadjuvant therapy. J Clin Oncol 2003; 21: 690-696
80. Shipley WU, Winter KA, Kaufman DS, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 1998; 16: 3576-3583
81. Hussain SA, Moffitt DD, Glaholm JG, Peake D, Wallace DM, James ND,. A phase I-II study of synchronous chemoradiotherapy for poor prognosis locally advanced bladder cancer. Ann Oncol 2001; 12: 929-935
82. Proverbs-Singh T, Chiu SK, Liu Z, et al. Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis. J Natl Cancer Inst 2012; 104: 1837-1840
83. Rene NJ, Cury FB, Souhami L,. Conservative treatment of invasive bladder cancer. Curr Oncol 2009; 16: 36-47
84. Zietman AL, Grocela J, Zehr E, et al. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder. Urology 2001; 58: 380-385
85. Pieras E, Palou J, Salvador J, Rosales A, Marcuello E, Villavicencio H,. Management and prognosis of transitional cell carcinoma superficial recurrence in muscle-invasive bladder cancer after bladder preservation. Eur Urol 2003; 44: 222-225